Drugs / AJU-C52
last change Aug 2024 re-read 3 minutes ago

AJU-C52

Developed for
essential hypertension
Investigated by
AJU Pharm Co., Ltd.

Trials 1

2023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT06416865 Jun → Dec 2022 essential hypertension AJU Pharm Co., Ltd. Unknown No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as AJU-C52 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06416865 ↗